Himuka AM Pharma Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 14

Himuka AM Pharma General Information

Description

Developer of a bioactive peptide intended for mucosal healing and clinical remission. The company specializes in researching and developing new drug seeds for improved adrenomedullin, enabling healthcare professionals to resolve unmet medical needs.

Contact Information

Website
www.himuka-am.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 5th Floor, Miyazaki 25 Building
  • 2-5-36 Takachiho-dori
  • Miyazaki City, Miyazaki 880-0812
  • Japan
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Life Sciences
Corporate Office
  • 5th Floor, Miyazaki 25 Building
  • 2-5-36 Takachiho-dori
  • Miyazaki City, Miyazaki 880-0812
  • Japan

Himuka AM Pharma Timeline

2021202220232024
Financing Round

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Himuka AM Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Secondary Transaction - Private 01-Mar-2023 Completed Clinical Trials - Phase 1
3. Later Stage VC (Series B) 14-Jan-2022 Completed Pre-Clinical Trials
2. Accelerator/Incubator 24-Jun-2019 $5.73M Completed Startup
1. Early Stage VC (Series A) 19-Jun-2018 $5.73M $5.73M Completed Startup
To view Himuka AM Pharma’s complete valuation and funding history, request access »

Himuka AM Pharma Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
B preferred
A preferred
To view Himuka AM Pharma’s complete cap table history, request access »

Himuka AM Pharma Patents

  • 6

    Total Documents Applications and Grants

  • Total Patents Families

  • 6

    Granted

  • Pending

  • Expiring in next 12 mo

Himuka AM Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2016324119-B2 Long-acting adrenomedullin derivative Active 18-Sep-2015
AU-2020200934-B2 Long-acting adrenomedullin derivative Active 18-Sep-2015
AU-2016324119-A1 Long-acting adrenomedullin derivative Active 18-Sep-2015
AU-2020200934-A1 Long-acting adrenomedullin derivative Active 18-Sep-2015
AU-2021254623-A1 Long-acting adrenomedullin derivative Active 18-Sep-2015 C07K14/575
To view Himuka AM Pharma’s complete patent history, request access »

Himuka AM Pharma Executive Team (2)

Name Title Board Seat
Hiroshi Shinjo Chief Executive Officer
Kazuo Kitamura Co-Founder
To view Himuka AM Pharma’s complete executive team members history, request access »

Himuka AM Pharma Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Dogan Beta Venture Capital Minority
Fiducia (Japan) Venture Capital Minority
KSP Corporation Minority
Nanto Capital Partners Corporate Venture Capital Minority
Venture Labo Investment Venture Capital Minority
You’re viewing 5 of 14 investors. Get the full list »

Ready to get started?

Request a free trial

Himuka AM Pharma FAQs

  • When was Himuka AM Pharma founded?

    Himuka AM Pharma was founded in 2017.

  • Who is the founder of Himuka AM Pharma?

    Kazuo Kitamura is the founder of Himuka AM Pharma.

  • Who is the CEO of Himuka AM Pharma?

    Hiroshi Shinjo is the CEO of Himuka AM Pharma.

  • Where is Himuka AM Pharma headquartered?

    Himuka AM Pharma is headquartered in Miyazaki City, Japan.

  • What industry is Himuka AM Pharma in?

    Himuka AM Pharma’s primary industry is Drug Discovery.

  • Is Himuka AM Pharma a private or public company?

    Himuka AM Pharma is a Private company.

  • What is Himuka AM Pharma’s current revenue?

    The current revenue for Himuka AM Pharma is .

  • How much funding has Himuka AM Pharma raised over time?

    Himuka AM Pharma has raised $11.2M.

  • Who are Himuka AM Pharma’s investors?

    Dogan Beta, Fiducia (Japan), KSP, Nanto Capital Partners, and Venture Labo Investment are 5 of 14 investors who have invested in Himuka AM Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »